Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of AD-120 vs AD-120A in Healthy Volunteers
NCT06916130Phase 1Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-120 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma concentration-time curve over a dosing interval at steady state, The time of peak concentration after single dose and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
AD-120
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06916130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916130.